References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;1–24.
- Wu Y, Song Z, Sun K, et al. A novel scoring system based on peripheral blood test in predicting grade and prognosis of patients with glioma. Onco Targets Ther. 2019;12:11413–11423. doi:10.2147/OTT.S23659831920331
- Elgendy M, Cirò M, Hosseini A, et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3β-MCL-1 axis. Cancer Cell. 2019;35(5):798–815.e5. doi:10.1016/j.ccell.2019.03.00731031016
- De P, Carlson JH, Leyland-Jones B, et al. Role of “oncogenic nexus” of CIP2A in breast oncogenesis: how does it work? Am J Cancer Res. 2015;5(9):2872–2891.26609493
- Soofiyani SR, Hejazi MS, Baradaran B. The role of CIP2A in cancer: a review and update. Biomed Pharmacother. 2017;96:626–633. doi:10.1016/j.biopha.2017.08.14629035828
- Yang X, Qu K, Tao J, et al. Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;495(2):1807–1814. doi:10.1016/j.bbrc.2017.11.12429175329
- Ji J, Zhen W, Si Y, et al. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer. Cancer Biomark. 2018;21(2):307–316. doi:10.3233/CBM-17041629103022
- Guo B, Wu S, Zhu X, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39(1):e102190. doi:10.15252/embj.201910219031755573
- Dissaux G, Basse V, Schick U, et al. Prognostic value of 18F-FET PET/CT in newly diagnosed WHO 2016 high-grade glioma. Medicine (Baltimore). 2020;99(5):e19017. doi:10.1097/MD.000000000001901732000446
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108. doi:10.1038/nprot.2008.7318546601
- Stavast CJ, Erkeland SJ. The non-canonical aspects of MicroRNAs: many roads to gene regulation. Cells. 2019;8(11). doi:10.3390/cells8111465
- Perconti G, Rubino P, Contino F, et al. RIP-Chip analysis supports different roles for AGO2 and GW182 proteins in recruiting and processing microRNA targets. BMC Bioinformatics. 2019;20(Suppl 4):120. doi:10.1186/s12859-019-2683-y30999843
- Ramos F, Villoria MT, Alonso-Rodríguez E, et al. Role of protein phosphatases PP1, PP2A, PP4 and Cdc14 in the DNA damage response. Cell Stress. 2019;3(3):70–85. doi:10.15698/cst2019.03.17831225502
- Kauko O, Westermarck J. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer. Int J Biochem Cell Biol. 2018;96:157–164. doi:10.1016/j.biocel.2018.01.00529355757
- Cha G, Xu J, Xu X, et al. High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis. Onco Targets Ther. 2017;10:5907–5914. doi:10.2147/OTT.S14825029276394
- Wang X, Yang R, Wang Q, et al. Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance. Medicine (Baltimore). 2019;98(36):e17028. doi:10.1097/MD.000000000001702831490389
- Kobayashi H, Tomari Y. RISC assembly: coordination between small RNAs and argonaute proteins. Biochim Biophys Acta. 2016;1859(1):71–81. doi:10.1016/j.bbagrm.2015.08.00726303205
- Liu H, Lei C, He Q, et al. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer. 2018;17(1):64. doi:10.1186/s12943-018-0765-529471827
- Tian Y, Xia S, Ma M, et al. LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther. 2019;12:10569–10578. doi:10.2147/OTT.S22965931819536
- Cui Y, Chen LG, Yao HB, et al. Upregulation of microRNA-383 inhibits the proliferation, migration and invasion of colon cancer cells. Oncol Lett. 2018;15(1):1184–1190. doi:10.3892/ol.2017.740929399173